Summit Therapeutics SMMT Licensing agreements — Deferred revenue for enrollment milestone
Discontinued — last reported Q3 '21
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept smmt:ContractWithCustomerLiabilityEnrollmentMilestone.
The official record: Summit Therapeutics’s 10-Q, filed May 11, 2023, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's licensing agreements — deferred revenue for enrollment milestone.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's licensing agreements — deferred revenue for enrollment milestone?
- Summit Therapeutics (SMMT) reported licensing agreements — deferred revenue for enrollment milestone of $1.25M in Q3 2021.
- What does licensing agreements — deferred revenue for enrollment milestone mean?
- Prepaid revenue tied to specific clinical trial enrollment targets that the company has yet to achieve.
- How do you interpret licensing agreements — deferred revenue for enrollment milestone?
- An increase reflects new milestone-based funding, while a decrease signals that the company is hitting its clinical enrollment targets.
- How does licensing agreements — deferred revenue for enrollment milestone compare across companies?
- Common in clinical-stage biotech companies with co-development agreements.